Drug Discovery & Research

Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving pharma drug discovery and development. The invention of new medicines, and the improvement of existing drugs constitute the development firms in pharmaceutical industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks.
Germany is forecast to have highest increase in pharmaceutical market value at € 11.4bn. Novartis is forecast to reduce its pharma R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20 pharmaceutical industries, Celgene and Regeneron are forecast to grow their pharma R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total pharma R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.
Persistent innovative development is one of the eminent characters of pharmaceutical industry. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving pharma drug discovery and development. The invention of new medicines, and the improvement of existing drugs constitute the development firms in pharmaceutical industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks.
Germany is forecast to have highest increase in pharmaceutical market value at € 11.4bn. Novartis is forecast to reduce its pharma R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20 pharmaceutical industries, Celgene and Regeneron are forecast to grow their pharma R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total pharma R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.
  • Challenges in Drug Discovery
  • Criteria for Target Selection
  • Advancements of In vitro studies
  • Enhancements of In vivo studies
  • Quality by Design
  • Random Screening
  • Molecular Designing
  • Drug Metabolites
  • Genomic Technologies
  • Proteomic Technologies
  • Nanotechnology
  • Microencapsulation: Methods and Industrial Applications

Related Conference of Drug Discovery & Research

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Drug Discovery & Research Conference Speakers

Recommended Sessions

Related Journals

Are you interested in